Related Experiment Video
Updated: Mar 30, 2026
07:02
Exploring the Arginine Methylome by Nuclear Magnetic Resonance Spectroscopy
Published on: December 16, 2021
1.9K
Relationship between Arginase 1 and Arginase 2 levels and genetic polymorphisms with erectile dysfunction
Riccardo Lacchini1, Jaqueline J Muniz1, Yuri T D A Nobre2
1Department of Psychiatric Nursing and Human Sciences, Ribeirao Preto College of Nursing, University of Sao Paulo, Av. Bandeirantes, 3900, 14049-900 Ribeirao Preto, SP, Brazil.
Nitric Oxide : Biology and Chemistry
|November 6, 2015
Summary
Plasma Arginase 2 levels are linked to erectile dysfunction (ED) risk. Genetic variations in Arginase 1 influence ED severity, suggesting potential biomarkers for this condition.
Area of Science:
- Biochemistry
- Genetics
- Urology
Background:
- Arginase 1 and Arginase 2 enzymes metabolize l-arginine, competing with nitric oxide synthases.
- Elevated arginase activity can decrease nitric oxide production, potentially contributing to endothelial dysfunction and conditions like erectile dysfunction (ED).
Purpose of the Study:
- To investigate the association between plasma levels of Arginase 1 and 2, plasma arginase activity, and genetic factors with the risk and severity of ED.
Main Methods:
- Plasma concentrations of Arginase 1 and 2 were measured using ELISA.
- Plasma arginase activity was determined spectrophotometrically.
- Genotyping of ARG1 and ARG2 single nucleotide polymorphisms (SNPs) was performed using Taqman assays.
Main Results:
- Higher plasma concentrations of Arginase 2 were observed in patients with clinical ED and correlated with an increased risk.
- Specific Arginase 1 genotypes (rs2781659 AA and rs2781667 TT) and the ARG1 GTCC haplotype were associated with ED severity, indicated by lower or higher International Index of Erectile Function (IIEF) scores, respectively.
Conclusions:
- Plasma Arginase 2 concentration may serve as a predictive risk factor for ED.
- Genetic variations in Arginase 1 play a role in modulating the severity of ED.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
68
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
109
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
62
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
62
01:27Pharmacogenetics of Drug Metabolism: Overview
113
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
113
01:20Disorders of the Male Reproductive System
5.4K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.4K
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
158
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
158